The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Angela B. Smith, MD, MS, regarding the significance of this approval for providers and patients.
The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Dr. Angela Smith, of UNC Lineberger Comprehensive Cancer Center, regarding the significance of this approval for providers and patients. The interview took place on May 1, 2020. Dr. Smith serves on the study advisory committee for UroGen Pharma.
More from Urology Times®:
UTUC therapy yields high rate of disease eradication, durability
Blue light cystoscopy enables earlier detection of invasive bladder tumors
Further Evaluation of Tivozanib Shows Promise for Relapsed, Refractory Renal Cell Carcinoma
Blue light cystoscopy decreases risk of recurrence, progression in NMIBC
May 9th 2024“The results of the BRAVO study performed within the VA health care system showed significant decreases in the risk of recurrence and progression, as well as the potential for improved overall survival in patients who received a BLC compared to patients who received WLC only,” says Stephen B. Williams, MD, MBA, MS, FACS, FACHE.